Evidence for Steroid Control of the Metabolism of Profibrinolysin

L. O Pilgeram; B. A Amundson; P. E Lofgren

doi:10.1055/s-0038-1654809

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1964; 11(01): 094-098
DOI: 10.1055/s-0038-1654809

Originalarbeiten — Original Articles — Travaux Originaux

Schattauer GmbH

Evidence for Steroid Control of the Metabolism of Profibrinolysin

L. O Pilgeram

¹Arteriosclerosis Research Laboratory, St. Barnabas Hospital Research Foundation and the Department of Physiology, University of Minnesota School of Medicine, Minneapolis, Minnesota

,

B. A Amundson

¹Arteriosclerosis Research Laboratory, St. Barnabas Hospital Research Foundation and the Department of Physiology, University of Minnesota School of Medicine, Minneapolis, Minnesota

,

P. E Lofgren

¹Arteriosclerosis Research Laboratory, St. Barnabas Hospital Research Foundation and the Department of Physiology, University of Minnesota School of Medicine, Minneapolis, Minnesota

› Author Affiliations

Abstract

Summary

Daily therapy with 5 mg of norethynodrel and 0.075 mg of ethynylestra- diol-3-methyl ether (Enovid) is associated with a 34.7% (P < 0.001) increase in the activity of human serum profibrinolysin (plasminogen).

Full Text

References

References
1 Egeberg O, Owren P. A. Oral Contraception and Blood Coagulability. Brit. med. J. 1963; 220.
2 Amundson B. A, Pilgeram L. O. Observations on a Relationship Between Steroid Metabolism and the Concentration of Plasma Fibrinogen. Thrombos. Diathes. haemorrh. (Stuttg) 10: 400 1964;
3 Dieckmann W. J, Wegner C. R. Studies of Blood in Normal Pregnancy: Percentages and Grams per Kilogram of Serum Protein and Fibrin and Variations in Total Amount of Each. Arch. int. Med. 53: 353 1934;
4 Pechet L, Alexander B. Increased Clotting Factors in the Gravid: A Hypercoagulable State. New Engl. J. Med. 265: 1093 1961;
5 United States Food and Drug Administration Report on Enovid. J. Amer. med. Ass. 185: 776 1963;
6 Pilgeram L. O. Relation of Plasma Fibrinogen Concentration Changes to Human Arteriosclerosis. J. appl. Physiol. 16: 660 1961;
7 Poller L. Thrombosis and Factor VII Activity. J. clin. Path. 10: 348 1957;
8 Norman P. S. Studies of the Plasmin System. I. Measurement of Human and Animal Plasminogen, Measurement of an Activator in Human Serum. J. exp. Med. 106: 423 1957;
9 Norman P. S. Studies of the Plasmin System. II. Inhibition of Plasmin by Serum of Plasma. J. exp. Med. 108: 53 1958;
10 Remmert L. F, Cohen P. P. Partial Purification and Properties of a Proteolytic Enzyme in Human Serum. J. biol. Chem. 181: 431 1949;
11 Christensen L. R, Leod CMMc. Methods for Measuring the Activity of Components of the Streptococcal Fibrinolytic System and Streptococcal Desoxyribonuclease. J. gen. Physiol. 28: 559 1945;
12 Christensen L. R. A Proteolytic Enzyme of Serum: Characterization, Activation, and Reaction with Inhibitors. J. clin. Invest 28: 163 1949;